SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc. (South San Francisco, California) Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma